Atox Bio Signs $24M Contract With BARDA

September 29, 2014 | Atox Bio, a clinical stage company developing immuneumodulators for severe infections, announced that it was awarded with a $24 million contract for the development of AB103. According to the company’s reports, Atox Bio was awarded the contract by the Biomedical Advanced Research and Development Authority (BARDA), and that the contract will last for 4.5 years, until the company’s AB103 drug for the treatment of Necrotizing Soft Tissue Infections (NSTI) is completed. The BARDA contract itself is worth $4.4 million over a period of 18 months, after which, and according to progress made on the AB103 drug, the authority will bring the value of the award to the full $24 million. Atox Bio has completed a Phase II trial on patients with NSTI and saw meaningful improvement in the serious condition.